default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar

Lee Han-soo  Published 2019.07.19  17:01  Updated 2019.07.19 17:01

공유
default_news_ad2

Samsung Bioepis said that the European Medicines Agency (EMA) has started evaluating its application to market SB8, an Avastin biosimilar product.

Samsung Bioepis headquarters in Songdo, Incheon.

The company submitted a marketing authorization application to the EMA in June. With the start of the screening process, Samsung Bioepis has become the first Korean firm to kick off its marketing approval process for the anticancer, antibody biosimilar in the global market.

SB8 is the second oncology biosimilar developed by Samsung Bioepis and will mark the fifth biosimilar product that the company plans to launch in the global market. The company currently sells Benepali, Flixabi, Imraldi, and Ontruzant in the EU. The company also plans to present global phase 3 trial results for SB8 at the European Society for Medical Oncology in September.

Avastin, developed by Roche, treats metastatic colorectal cancer, non-small cell lung cancer, and metastatic breast cancer. The drug recorded a global sale of 8.2 trillion won ($6.9 billion) last year.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch